Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
MedinCell Logo
MedinCell Growth Score
67
CB Rank
57309
Heat Score
68
MedinCell is an injectable slow-release drug specialist company.
Founded
obfuscation
PublicPost-IPO Equity Jacou, Languedoc-Roussillon, France101-250 www.medincell.com/
Pharmaceutical
Overview

MedinCell
Total Funding
obfuscation
Growth Score
67
Heat Score
68

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score67
-15 pts
in past quarter
Heat Score 68
-16 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About MedinCell

CB Rank
57309
MedinCell is an injectable slow-release drug specialist company.
Founded
obfuscation
PublicPost-IPO Equity Jacou, Languedoc-Roussillon, France101-250 www.medincell.com/
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Grant
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Medincell SA
Operating Status Active
Stock Symbol  EPA:MEDCL
Company Type For Profit
Founders  Anh N'Guyen, Christophe Douat
About the Company
MedinCell is an injectable slow-release drug specialist company.
Contact Email communication@medincell.com
Predictions & Insights

Growth Insight

See this Growth Insight
MedinCell is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

UZEDY®
A monthly or bi-monthly subcutaneous injectable risperidone formulation for treating schizophrenia.
mdc-TJK (Olanzapine LAI)
A once-monthly subcutaneous long-acting injectable of olanzapine for schizophrenia treatment, currently in Phase 3 clinical trials.

Research & Development

MedinCell is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 12
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 12
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
4
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Kurma Partners Logo
Kurma Partners
—
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
—
Kurma Partners Logo
Kurma Partners
—
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
—
Kurma Partners Logo
Kurma Partners
—
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
—
Kurma Partners Logo
Kurma Partners
—
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
—
Kurma Partners Logo
Kurma Partners
—
Post-IPO Equity - MedinCell Logo
Post-IPO Equity - MedinCell
—
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 2 Contacts 82

Employee Profiles

News

News and Press

News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 20, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

4,373
76.9%
 in past month

IT Spend

$1.6MThis year, MedinCell is projected to spend $1.6M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Live Science Logo
Live Science
78
Linux Lite Logo
Linux Lite
78
Newsweek Logo
Newsweek
78

Actively Used Products

26MedinCell uses 26 technology products and services including HTML5, Lightbox, and  Comodo PositiveSSL Certificates, according to G2 Stack.

Active Website Tech Count

35MedinCell is actively using 35 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.

Total IP

10MedinCell has registered 10 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is MedinCell's headquarters? MedinCell is located in Jacou, Languedoc-Roussillon, France.Who invested in MedinCell? MedinCell has 19 investors including Kurma Partners and  Affinity Asset Advisors.When was the last funding round for MedinCell? MedinCell closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are MedinCell's competitors? Alternatives and possible competitors to MedinCell may include Angelini Pharma, Idorsia, and  Nutriband.How much funding has MedinCell raised to date? MedinCell has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|